ConductScience.org, home

Paper29285367

Clinical study on collagen gel droplet-embedded culture drug sensitivity test for multidrug combination chemotherapy and super selective intra-arterial infusion chemoradiotherapy in oral squamous cell carcinoma.

Sakuma K and 7 others. Mol Clin Oncol, 2017. Cited by 4 papers, by iCite.

Cite this record

ConductScience Library. Clinical study on collagen gel droplet-embedded culture drug sensitivity test for multidrug combination chemotherapy and super selective intra-arterial infusion chemoradiotherapy in oral squamous cell carcinoma. Papers, record 29285367. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/29285367

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Clinical study on collagen gel droplet-embedded culture drug sensitivity test for multidrug combination chemotherapy and super selective intra-arterial infusion chemoradiotherapy in oral squamous cell carcinoma.
PubMed
Journal
Mol Clin Oncol
PubMed
Year
2017
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
4
iCite
Relative citation ratio, by iCite
0.17
iCite
Revised in PubMed
2020-10-01
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Sakuma KKaname
2Tamura RRyuki
3Hanyu SShintaro
4Takahashi HHaruka
5Sato HHideaki
6Oneyama TTakahiro
7Yamaguchi AAkira
8Tanaka AAkira

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References30

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
19987506[Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent head and neck cancer].Gan To Kagaku Ryoho1999https://conductscience.org/library/papers/9987506PubMed
219211574
Systemic chemotherapy with cisplatin plus 5-FU (PF) for recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): efficacy and safety of a lower dose of PF (80/800) at a single institution in Japan.
Jpn J Clin Oncol2009https://conductscience.org/library/papers/19211574PubMed
39226312Efficacy of targeted supradose cisplatin and concomitant radiation therapy for advanced head and neck cancer: the Memphis experience.Int J Radiat Oncol Biol Phys1997https://conductscience.org/library/papers/9226312PubMed
424649243Clinical predictive value of in vitro anticancer drug sensitivity test for the therapeutic effect of adjuvant chemotherapy in patients with stage II-III colorectal cancer.Mol Clin Oncol2013https://conductscience.org/library/papers/24649243PubMed
515735120
Supradose intra-arterial cisplatin and concurrent radiation therapy for the treatment of stage IV head and neck squamous cell carcinoma is feasible and efficacious in a multi-institutional setting: results of Radiation Therapy Oncology Group Trial 9615.
J Clin Oncol2005https://conductscience.org/library/papers/15735120PubMed
61732427A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck.J Clin Oncol1992https://conductscience.org/library/papers/1732427PubMed
715628760[In vitro chemosensitivity test for hepatocellular carcinoma using collagen-gel droplet embedded cultures].Gan To Kagaku Ryoho2004https://conductscience.org/library/papers/15628760PubMed
821528231An in vitro chemosensitivity test for solid human tumors using collagen gel droplet embedded cultures.Int J Oncol1997https://conductscience.org/library/papers/21528231PubMed
924318670Stratified phase II trial to establish the usefulness of the collagen gel droplet embedded culture-drug sensitivity test (CD-DST) for advanced gastric cancer.Gastric Cancer2014https://conductscience.org/library/papers/24318670PubMed
1028105171Collagen gel droplet-embedded culture drug sensitivity testing in squamous cell carcinoma cell lines derived from human oral cancers: Optimal contact concentrations of cisplatin and fluorouracil.Oncol Lett2016https://conductscience.org/library/papers/28105171PubMed
1114735175Phase I trial of concurrent chemoradiotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF) in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).Br J Cancer2004https://conductscience.org/library/papers/14735175PubMed
124289605In vitro test for sensitivity of tumor to carcinostatic agents.Gan1966https://conductscience.org/library/papers/4289605PubMed
1321547692Heterogeneity of anticancer drug sensitivity in squamous cell carcinoma of the tongue.Hum Cell2011https://conductscience.org/library/papers/21547692PubMed
1417960012Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.N Engl J Med2007https://conductscience.org/library/papers/17960012PubMed
1517960013Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.N Engl J Med2007https://conductscience.org/library/papers/17960013PubMed
1610659592An in vitro chemosensitivity test for colorectal cancer using collagen-gel droplet embedded cultures.Kurume Med J1999https://conductscience.org/library/papers/10659592PubMed
1719097774New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).Eur J Cancer2009https://conductscience.org/library/papers/19097774PubMed
1818487915[Collagen gel droplet-embedded culture drug sensitivity test in human breast cancer].Gan To Kagaku Ryoho2008https://conductscience.org/library/papers/18487915PubMed
1919746222The efficacy of an induction chemotherapy combination with docetaxel, cisplatin, and 5-FU followed by concurrent chemoradiotherapy in advanced head and neck cancer.Cancer Res Treat2007https://conductscience.org/library/papers/19746222PubMed
203004363[A cooperative phase II study of cisplatin in patients with head and neck cancer].Gan To Kagaku Ryoho1986https://conductscience.org/library/papers/3004363PubMed

See all 30 referencesDownload CSV of references

Cited by2

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.

PMIDTitleJournalYearIn PapersSource
34646385Benefits of functional assays in personalized cancer medicine: more than just a proof-of-concept.Theranostics2021https://conductscience.org/library/papers/34646385PubMed
31832190Identification of the optimal cetuximab concentration that is effective against oral squamous cell carcinoma in collagen gel droplet embedded culture drug sensitivity testing.Mol Clin Oncol2020https://conductscience.org/library/papers/31832190PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/29285367

GET https://conductscience.org/api/papers/v1/29285367/references?page=2